Y-Intercept (HK)’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.75M Buy
+11,799
New +$2.73M 0.06% 469
2026
Q2
– Sell
-13,146
Closed -$2.58M – 1802
2026
Q1
$2.58M Sell
13,146
-16,759
-56% -$3.26M 0.05% 598
2025
Q4
$5.19M Buy
+29,905
New +$5.45M 0.12% 220
2025
Q2
– Sell
-7,258
Closed -$1.23M – 1702
2025
Q1
$1.23M Buy
+7,258
New +$1.19M 0.08% 333
2024
Q3
– Sell
-11,658
Closed -$1.6M – 1418
2024
Q2
$1.6M Buy
+11,658
New +$1.6M 0.09% 317
2023
Q4
– Sell
-31,520
Closed -$3.84M – 1313
2023
Q3
$3.84M Buy
31,520
+27,433
+671% +$3.66M 0.38% 37
2023
Q2
$574K Buy
+4,087
New +$563K 0.06% 507
2022
Q2
– Sell
-3,008
Closed -$412K – 920
2022
Q1
$412K Buy
+3,008
New +$419K 0.09% 340
2021
Q4
– Sell
-12,215
Closed -$1.78M – 629
2021
Q3
$1.78M Buy
12,215
+6,062
+99% +$887K 0.32% 83
2021
Q2
$812K Buy
6,153
+3,994
+185% +$523K 0.21% 140
2021
Q1
$277K Buy
+2,159
New +$266K 0.07% 440

Other funds holding DGX

Y-Intercept (HK)'s DGX Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Quest Diagnostics (DGX) in Q3 2026: 11,799 shares worth $2.75M. The stake represents 0.06% of the portfolio and ranks #469 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in DGX as recently as Q1 2026.

Y-Intercept (HK) first reported a position in DGX in Q1 2021 and has held it in 11 quarters since. The position peaked at $5.19M in Q4 2025. 703 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Y-Intercept (HK) held 11,799 shares of Quest Diagnostics worth $2.75M as of Q3 2026.
  • Quest Diagnostics was a new Y-Intercept (HK) position in Q3 2026.
  • Quest Diagnostics made up 0.06% of Y-Intercept (HK)'s portfolio in Q3 2026, its #469 holding.
  • Y-Intercept (HK) first reported a position in Quest Diagnostics in Q1 2021 and has held it in 11 quarters since.
  • Y-Intercept (HK)'s Quest Diagnostics position peaked at $5.19M in Q4 2025.
  • 703 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.